Orforglipron is FDA-approved. It is not a peptide, and 6 mg is not one of its strengths.

Why this note exists

Orforglipron arrives in the research market carrying two claims that are easy to repeat and worth separating. The first is "FDA-approved," which is now true, and which for once means roughly what a buyer would assume: an approved oral drug for weight management in adults, on the strength of two large randomized placebo-controlled trials. The second is that it belongs on a peptide shelf at all. It does not. Every phase 3 report describes it as a small-molecule, non-peptide GLP-1 receptor agonist, and the label's chemistry section gives a molecular formula, a molecular weight of 902.0 g/mol, and the observation that the substance is insoluble in water.[1][5][6]

In the index generated on August 15, 2026, 11 of 112 vendors carried an orforglipron listing — twelve listings, sixty-seventh of 83 compounds by vendor coverage.[12] That is a thin corner of the market, not a bestseller. It is also, unusually, a corner where the route matches: ten of the twelve listings name a capsule or tablet, which is at least the right form for a drug that cannot be dissolved in bacteriostatic water.[1][12] The mismatch is in the milligrams.

A note on what kind of evidence this is: every efficacy figure below is human data, carrying its trial, design, estimand and participant count. One paragraph reports rodent findings and is labeled as such — it happens to be the most interesting paragraph in the label. Sponsor-funded and sponsor-authored analyses are identified where that is the case, and pepmg does not convert a labeled dose into a protocol for a research capsule.

The approval

What FDA approved, in FDA's words

The indication runs to one sentence: Foundayo "is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition."[1] The approval letter states the same scope and records the application as "received January 20, 2026."[2] There is one limitation of use, and it is short: "Concomitant use with another GLP-1 receptor agonist is not recommended."[1]

The dosing schedule is the part that gets compressed in retelling, and it is almost entirely a titration schedule. The starting dosage is 0.8 mg once daily. After at least 30 days it increases to 2.5 mg; after at least 30 days more, to 5.5 mg; and it "may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability," to a maximum of 17.2 mg.[1] The label states the escalation exists "to reduce the risk of gastrointestinal (GI) adverse reactions," instructs that tablets be swallowed whole and not broken, crushed or chewed, and directs that if seven or more consecutive doses are missed the patient "reinitiate dosage escalation at a lower dosage."[1] Reaching the middle of the range takes two months by design.

Two procedural facts belong here. FDA's announcement describes the decision as "[i]ssued 50 days after filing — and 294 days before the application's PDUFA date of January 20, 2027," calls it "the first new molecular entity (NME) approved under the program," and adds that it "is also the fastest approval of an NME since 2002."[3] The agency describes the Commissioner's National Priority Voucher pilot as launched in 2025, with 18 vouchers awarded and six decisions issued at that point, a target decision timeline of two months, and benefits consisting of "enhanced communications and rolling review."[3] Notably, Drugs@FDA records the review priority for the original application as standard — the speed came from the voucher pathway, not from a priority-review designation.[4]

And, as with several other compounds in this index, no advisory committee saw it. The approval letter states: "Your application for Foundayo was not referred to an FDA advisory committee because there were no controversial issues that would benefit from advisory committee discussion."[2] That is a routine sentence in approval letters. It is worth knowing anyway, because "FDA-approved" and "an expert panel reviewed it in public" are frequently treated as the same claim, and here only the first is true.

The pivotal evidence

Two trials, 4,740 adults, and three different versions of one number

The efficacy package is two 72-week randomized, double-blind, placebo-controlled trials.[1] ATTAIN-1 enrolled 3,127 adults with obesity, or overweight plus at least one weight-related comorbid condition, with type 2 diabetes excluded; mean baseline weight 103.2 kg, mean BMI 37.[1][5][7] ATTAIN-2 enrolled 1,613 adults with a BMI of 27 or above and type 2 diabetes, baseline HbA1c 7–10%, across 136 sites in ten countries.[1][6][8] Both were funded by Eli Lilly, and both author lists include Lilly employees and shareholders.[5][6]

Trial results as reported in the primary publications; the pooled hepatic analysis is a separate sponsor-authored paper covering the wider phase 3 programme.[5][6][11]

The primary endpoint in both trials was the mean percent change in body weight from baseline to week 72, "as assessed according to the treatment-regimen estimand in the intention-to-treat population" — that is, using data from everyone randomized, regardless of whether they stopped the drug.[5] ATTAIN-2 states the choice explicitly: the treatment-regimen estimand "was the primary estimand, with the efficacy estimand considered supportive."[6] This matters more than it sounds, because it is where the headline number comes from.

One trial, one dose, three published numbers. For the 36 mg arm of ATTAIN-1 at 72 weeks: the New England Journal of Medicine reports −11.2% (95% CI −12.0 to −10.4) under the primary estimand.[5] FDA's own tabulation of the same arm in the label reports −11.1%, a 9.0-point difference from placebo.[1] The figure that travelled furthest in coverage of the trial, 12.4%, is the efficacy estimand — the on-treatment analysis the trial's own authors designated supportive rather than primary.[5][6] None of the three is wrong. They answer slightly different questions, and the largest one answers the narrowest.

The responder figures follow the same pattern and are worth quoting whole, because "how much" and "how many" are different claims. Among ATTAIN-1 patients on 36 mg, 54.6% had a reduction of 10% or more, 36.0% had 15% or more, and 18.4% had 20% or more, against 12.9%, 5.9% and 2.8% of the placebo group.[5] Put the other way: at the highest dose studied, in the trial designed to show the drug at its best, roughly four in five participants did not reach 20% weight loss.

The gap

The trial and marketed formulations use different equivalent doses

This is the finding that made the note worth writing, and it is stated plainly in the label itself. The registry record for ATTAIN-1 lists the three active arms as "6 mg Orforglipron," "12 mg Orforglipron" and "36 mg Orforglipron," and both journal reports use those numbers throughout.[5][6][7] The label presents the same three arms of the same two trials as 5.5 mg, 9 mg and 17.2 mg.[1]

It is not a discrepancy; it is disclosed. The label's clinical studies section states that effectiveness was established "based on adequate and well-controlled trials of an investigational orforglipron formulation (Trials 1 and 2)," and that "[t]his section of labeling presents efficacy data from administration of the investigational orforglipron formulation shown as equivalent dosages of once daily FOUNDAYO."[1] The adverse-reactions section carries the identical sentence about the safety data, and the pharmacokinetics section notes that except in the food-effect study, "data were generated with the corresponding orforglipron investigational formulation."[1] The arm sizes confirm the mapping: the label's Trial 1 columns are 949 placebo and 723, 725 and 730, which sum to the 3,127 randomized in ATTAIN-1 at that trial's 3:3:3:4 ratio.[1][5][7]

Equivalent dosages is the language you use when two numbers are not interchangeable. A trial 6 mg and a marketed 5.5 mg are presented as producing comparable exposure; they are not presented as the same quantity of drug in the same vehicle. Which means the single most common number in the research market for this compound — 6 mg — is a dose of a formulation that is not the approved product, and is not a strength FDA approved.[1][12]

Two further numbers make the point concrete. First, that 6 mg arm was the lowest of the three tested, and its 72-week result under the primary estimand was −7.5% in ATTAIN-1 and −5.1% in ATTAIN-2 — not the number in the headlines.[5][6] Second, the label's own path to the equivalent strength runs 0.8 mg → 2.5 mg → 5.5 mg with at least 30 days at each step, so a patient on the approved product reaches that level no sooner than day 61.[1] In pepmg's index, not one listing states a 0.8 mg unit.[12]

pepmg makes no claim about the contents of any vendor's capsule, and none of this says a listing is mislabeled. It says the number printed on it is a trial number rather than a label number, and that the two are documented, by the manufacturer, as different things.

Safety

A boxed warning that argues with itself, and six studies FDA ordered anyway

Foundayo carries a boxed warning for thyroid C-cell tumors, and it is worth reading rather than summarizing, because it is one of the clearest animal-versus-human statements in a current label. In products with GLP-1 receptor agonist activity "that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures." Then the twist: "Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents." And then the reason the warning stays: "While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined."[1] The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with MEN 2, and the label states that routine calcitonin monitoring or thyroid ultrasound "is of uncertain value for early detection."[1]

That paragraph is rodent data and the absence of rodent data, labeled as such. It is a class warning carried across on a mechanism argument, on a molecule that did not reproduce the rodent finding because it does not activate the rodent receptor. Neither the presence of the warning nor the negative rodent result settles the human question.

The everyday safety profile is gastrointestinal. Across a pooled safety population of 3,155 adults treated for up to 72 weeks, the adverse reactions reported in 5% or more were "nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss."[1] In ATTAIN-1, adverse events led to discontinuation in 5.3% to 10.3% of the orforglipron groups against 2.7% on placebo; in ATTAIN-2, 6.1% to 9.9% against 4.1%.[5][6] ATTAIN-2 reported ten deaths, six on orforglipron and four on placebo, with investigators deeming all unrelated to study treatment except one placebo case and one case in the 12 mg group, for which "no treatment-related association was reported."[6] A sponsor-authored pooled analysis of seven phase 3 trials, 11,220 participants followed up to 104 weeks, found hepatic adverse events balanced against comparators and no cases meeting drug-induced liver injury or Hy's Law criteria.[11]

What FDA still wants to know is in the approval letter, and it runs to 2043. Under section 505(o) the agency determined that spontaneous postmarketing adverse-event reporting "will not be sufficient to assess the signal of the serious risk of medullary thyroid cancer, and to identify unexpected serious risks of long-term use in pediatric patients with obesity, and exposure to orforglipron in pregnancy."[2] It required six postmarketing studies, among them a medullary thyroid carcinoma registry case series "of at least 15 years duration," a global pregnancy exposure registry, and a pediatric obesity registry of at least ten years.[2] Pediatric studies in ages 6 to 17 were deferred rather than waived, with the adolescent trial's final report due in December 2028.[2]

Two pharmacology facts round it out, because they are the sort of thing a class label hides. Orforglipron is metabolized primarily by hepatic CYP3A4, so the label caps the dose at 9 mg with a strong CYP3A4 inhibitor and advises avoiding strong inducers.[1] And its elimination half-life is approximately 29 to 49 hours — long enough that steady state takes about a week, and long enough that a mistimed escalation is not a same-day problem.[1] In moderate hepatic impairment exposure rose 1.7-fold, and in severe impairment 4.6-fold.[1]

Two more trials, because they will be quoted next

ACHIEVE-3 is the head-to-head. It is a 52-week, randomized, open-label, active-controlled non-inferiority trial in 1,698 adults with type 2 diabetes inadequately controlled on metformin, comparing orforglipron 12 mg and 36 mg against oral semaglutide 7 mg and 14 mg.[10] Under the treatment-regimen estimand, mean HbA1c changes from a baseline of 8.3% were −1.71% and −1.91% with orforglipron against −1.23% and −1.47% with semaglutide; non-inferiority was met and both orforglipron doses were superior to both semaglutide doses.[10] The trade appears in the tolerability columns: gastrointestinal adverse events in 58–59% of orforglipron participants against 37–45% on semaglutide, discontinuation for adverse events in 9–10% against 4–5%, and a larger mean pulse increase, 3.7 to 4.7 bpm against 1.0 to 1.5.[10] It is an HbA1c trial, not a weight-loss trial, and it was open-label.

ATTAIN-MAINTAIN is the one to watch for overreach. It is a double-blind, placebo-controlled phase 3b trial that randomized participants previously treated with tirzepatide (cohort 1, N = 205) or semaglutide (cohort 2, N = 171) in the earlier SURMOUNT-5 study to oral orforglipron or placebo.[9] At week 52, cohort 1 participants who had reached a weight plateau maintained a model-based estimate of 74.7% of their weight reduction on orforglipron against 49.2% on placebo; in cohort 2, 79.3% against 37.6%.[9] The authors name the limits themselves: there was no arm that simply continued the injectable, and the trial ran one year.[9] It shows a pill beating nothing at holding weight off, which is a real and useful result, and not the same as beating the injection.

Three things this note is not saying

First, it is not saying the fast approval was a shortcut through the evidence. The package FDA reviewed was two adequate and well-controlled 72-week trials in 4,740 randomized adults, with a wider phase 3 programme behind it; the CNPV pathway compressed review time, not trial size.[1][3][11] Whether a two-month target review is wise policy is a separate question this note takes no position on.

Second, it is not saying orforglipron does not work. Two large placebo-controlled trials met their primary endpoint under a conservative estimand, an active-controlled trial beat oral semaglutide on HbA1c, and the cardiometabolic secondaries moved in the expected direction.[1][5][6][10] On the published record this is one of the better-evidenced compounds in pepmg's index.

Third, it is not saying research listings are counterfeit or mislabeled. pepmg does not test product and makes no claim about what any capsule contains.

What it is saying is narrower, and it is three facts. Orforglipron is an approved oral tablet as of April 1, 2026. It is a small molecule, not a peptide, and it is insoluble in water. And the 6 mg that ten of twelve listings print is a dose of an investigational formulation, which the approved label re-expresses as 5.5 mg — a strength the approved product reaches only after two months of titration from 0.8 mg.[1][5][12]

Questions people are asking